Anlotinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Anlotinib
Accession Number
DB11885
Type
Small Molecule
Groups
Investigational
Description

Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.

Structure
Thumb
Synonyms
Not Available
External IDs
AL 3818 / AL-3818 / AL3818
Categories
UNII
GKF8S4C432
CAS number
1058156-90-3
Weight
Average: 407.445
Monoisotopic: 407.164519743
Chemical Formula
C23H22FN3O3
InChI Key
KSMZEXLVHXZPEF-UHFFFAOYSA-N
InChI
InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3
IUPAC Name
1-[({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl}oxy)methyl]cyclopropan-1-amine
SMILES
COC1=CC2=C(OC3=CC=C4NC(C)=CC4=C3F)C=CN=C2C=C1OCC1(N)CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
25017411
PubChem Substance
347828221
ChemSpider
45743493
ZINC
ZINC000117924202

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentMalignancies1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentCancer, Advanced2
1Not Yet RecruitingTreatmentLung Cancers1
1RecruitingTreatmentAdvanced Solid Tumors1
1RecruitingTreatmentAdvanced Stage / Lung Cancers1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1, 2Not Yet RecruitingTreatmentAdenocarcinomas / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
1, 2Not Yet RecruitingTreatmentEpithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer1
1, 2Not Yet RecruitingTreatmentLung Cancer Metastatic1
1, 2RecruitingPreventionHepatocellular,Carcinoma1
1, 2RecruitingTreatmentAdvanced Acral Malignant Melanoma1
1, 2RecruitingTreatmentAdvanced Biliary Adenocarcinoma/Hepatocellular Carcinoma1
1, 2RecruitingTreatmentAdvanced Cholangiocarcinoma1
1, 2RecruitingTreatmentCervical Carcinoma / Endometrial Carcinoma / Fallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Carcinoma1
1, 2RecruitingTreatmentColo-rectal Cancer1
1, 2RecruitingTreatmentEndometrial Cancer1
1, 2RecruitingTreatmentEwing's Tumor Metastatic1
1, 2RecruitingTreatmentGlioblastomas1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Small Cell Lung Cancer (SCLC) / Soft Tissue Sarcoma (STS) / Solid Tumor, Adult1
1, 2RecruitingTreatmentLung Cancers1
1, 2RecruitingTreatmentMetastatic Nasopharyngeal Carcinoma / Recurrent Nasopharyngeal Carcinoma1
1, 2RecruitingTreatmentRecurrent Glioblastoma1
1, 2TerminatedTreatmentCervical Cancers / Endometrial Cancer / Ovarian Cancer1
2Active Not RecruitingTreatmentAnlotinib / RCC1
2Active Not RecruitingTreatmentNeoplasm of Bone1
2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
2CompletedTreatmentAdvanced Malignancy1
2CompletedTreatmentEsophageal Squamous Cell Carcinoma (ESCC)1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentMalignancies1
2CompletedTreatmentSmall Cell Lung Cancer (SCLC)1
2CompletedTreatmentTumors1
2Enrolling by InvitationTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2Not Yet RecruitingTreatmentAdenocarcinomas / Distantly Metastatic Malignant Neoplasm / Head and Neck Carcinoma / Recurrent Disease1
2Not Yet RecruitingTreatmentAdvanced Head, Neck and Chest Cancer1
2Not Yet RecruitingTreatmentAnlotinib / Docetaxel / Neoplasms, Lung / Pemetrexed / S-11
2Not Yet RecruitingTreatmentAnlotinib / Durvalumab / Small Cell Lung Cancer (SCLC)1
2Not Yet RecruitingTreatmentAnlotinib / Lung Cancer Non-Small Cell Cancer (NSCLC) / PD-1/L1 Inhibitor1
2Not Yet RecruitingTreatmentCarcinoma NOS / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2Not Yet RecruitingTreatmentCarcinoma NOS / Neoplasms, Lung / Small Cell Lung Cancer (SCLC)1
2Not Yet RecruitingTreatmentChronic Graft Versus Host Disease1
2Not Yet RecruitingTreatmentEsophageal Squamous Cell Carcinoma (ESCC)2
2Not Yet RecruitingTreatmentExtensive-Stage Small Cell Lung Cancer1
2Not Yet RecruitingTreatmentGastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors1
2Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
2Not Yet RecruitingTreatmentHigh Grade Sarcoma / Soft Tissue Sarcoma Adult1
2Not Yet RecruitingTreatmentIIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy1
2Not Yet RecruitingTreatmentLung Cancer Metastatic / Lung Cancers1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
2Not Yet RecruitingTreatmentMSI-H or dMMR Advanced Solid Tumors1
2Not Yet RecruitingTreatmentNSCLC Stage IV1
2Not Yet RecruitingTreatmentSoft Tissue Sarcoma (STS)2
2Not Yet RecruitingTreatmentSoft Tissue Sarcoma (STS) / Undifferentiated Pleomorphic Sarcoma1
2Not Yet RecruitingTreatmentStage III Non-small-Cell Lung Cancer1
2RecruitingTreatmentAdvanced Hepatocellular Carcinoma1
2RecruitingTreatmentAnlotinib / Antineoplastic Agents / Neoplasms, Breast1
2RecruitingTreatmentAnlotinib / Chemo-free Therapy / Colorectal Cancers / First-line treatment / Immunotherapy / Sintilimab1
2RecruitingTreatmentAnlotinib / Early Stage / Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type / Open / Peg-aspargase / Phase Two / Single Center / Sintilimab1
2RecruitingTreatmentBiliary Tract Cancer1
2RecruitingTreatmentCarcinoma NOS / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung1
2RecruitingTreatmentEGFR Gene Mutations1
2RecruitingTreatmentExtensive-Stage Small Cell Lung Cancer1
2RecruitingTreatmentGastroenteropancreatic Neuroendocrine Tumor G31
2RecruitingTreatmentGastrointestinal Stromal Tumors1
2RecruitingTreatmentHepatocellular,Carcinoma3
2RecruitingTreatmentLocally Advanced Non-Small Cell Lung Cancer1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2RecruitingTreatmentMalignant Gliomas1
2RecruitingTreatmentNasopharyngeal Carcinoma1
2RecruitingTreatmentNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type2
2RecruitingTreatmentNon-Squamous Cell Non-small Cell Lung Cancer1
2RecruitingTreatmentNon-driver Mutation Advanced Non-Squamous Non Small Cell Lung Cancer / Non-Squamous Non Small Cell Lung Cancer1
2RecruitingTreatmentSarcomas1
2RecruitingTreatmentSmall Cell Lung Cancer (SCLC)2
2RecruitingTreatmentSoft Tissue Sarcoma (STS)2
2RecruitingTreatmentStereotactic Body Radiation Therapy1
2RecruitingTreatmentThyroid Cancers1
2RecruitingTreatmentUnresectable Stage III Non-small Cell Lung Cancer1
2RecruitingTreatmentRefractory Small cell lung cancer1
2, 3Active Not RecruitingBasic ScienceLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3Active Not RecruitingTreatmentDifferentiated Thyroid Cancer (DTC)1
2, 3Active Not RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2, 3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3CompletedTreatmentMedullary Thyroid Cancer (MTC)1
2, 3CompletedTreatmentMetastatic Colorectal Cancer (MCRC)1
2, 3RecruitingTreatmentAdvanced Solid Tumors1
2, 3RecruitingTreatmentMalignant Neoplasm of Stomach1
2, 3RecruitingTreatmentSmall Cell Lung Cancer (SCLC)1
3Not Yet RecruitingTreatmentExtensive Small Cell Lung Cancer1
3Not Yet RecruitingTreatmentSmall Cell Lung Cancer (SCLC)1
3Not Yet RecruitingTreatmentSquamous Non-Small Cell Lung Cancer1
3RecruitingTreatmentAlveolar Soft Part Sarcoma (ASPS) / Leiomyosarcomas / Soft-Tissue Sarcoma / Synovial Sarcoma1
4Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4RecruitingTreatmentAdvanced Non-squamous NSCLC1
Not AvailableNot Yet RecruitingTreatmentCancer of Liver1
Not AvailableNot Yet RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer3
Not AvailableRecruitingTreatmentAdvanced Solid Tumors1
Not AvailableRecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00238 mg/mLALOGPS
logP3.7ALOGPS
logP3.35ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)16.65ChemAxon
pKa (Strongest Basic)9.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area82.39 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity110.65 m3·mol-1ChemAxon
Polarizability42.95 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Ethers
Direct Parent
Diarylethers
Alternative Parents
Quinolines and derivatives / Indoles / Anisoles / Alkyl aryl ethers / Substituted pyrroles / Pyridines and derivatives / Aryl fluorides / Heteroaromatic compounds / Azacyclic compounds / Organofluorides
show 2 more
Substituents
Diaryl ether / Quinoline / Indole / Indole or derivatives / Anisole / Phenol ether / Alkyl aryl ether / Aryl fluoride / Aryl halide / Benzenoid
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:57 / Updated on March 01, 2020 21:01

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates